Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression

Adel Gabr(Tokushima University), Yasuhiko Nishioka(Tokushima University), Hirohisa Ogawa(Tokushima University), Yoichiro Moriya(Tokushima University), Hisatsugu Goto(Tokushima University), Atsuro Saijo(Tokushima University), Masaki Hanibuchi(Tokushima University), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Takuya Kuramoto(Tokushima University), Minako Suzuki, Saburo Sone(Io Therapeutics (United States)), Satoshi Sakaguchi(Tokushima University Hospital)
Clinical & Experimental Metastasis
December 14, 2011
10.1007/s10585-011-9443-3
Cited by 7

Related Papers

Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Expression profiles of non-small cell lung cancers on cDNA microarrays: Identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs
|Oncogene|2003|324
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)
|Human Molecular Genetics|2004|175
The Neuromedin U-Growth Hormone Secretagogue Receptor 1b/Neurotensin Receptor 1 Oncogenic Signaling Pathway as a Therapeutic Target for Lung Cancer
|Cancer Research|2006|134
Plakophilin 3 Oncogene as Prognostic Marker and Therapeutic Target for Lung Cancer
|Cancer Research|2005|124